COVID-19 vaccination in individuals with inflammatory rheumatic diseases

Alla Skapenko; Hendrik Schulze-Koops

doi:10.1038/s41584-022-00892-3

COVID-19 vaccination in individuals with inflammatory rheumatic diseases

Nat Rev Rheumatol. 2023 Feb;19(2):76-77. doi: 10.1038/s41584-022-00892-3.

Authors

Alla Skapenko¹, Hendrik Schulze-Koops²

Affiliations

¹ Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig Maximilians University of Munich, Munich, Germany.
² Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig Maximilians University of Munich, Munich, Germany. Hendrik.Schulze-Koops@med.uni-muenchen.de.

Abstract

Since the start of the SARS-CoV-2 vaccination campaign, our knowledge of the effects of vaccines in people with inflammatory rheumatic diseases has remained incomplete. In particular, the effects of immunomodulatory therapies on vaccine success are poorly understood. Three notable papers from the past year have helped to fill these knowledge gaps.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines / therapeutic use
COVID-19* / prevention & control
Humans
Rheumatic Diseases* / drug therapy
Vaccination

Substances

COVID-19 Vaccines